DiaCarta: Jack Kaye
DiaCarta has appointed Jack Kaye as an independent board member who will serve as the chairman of its audit committee.
Kaye, a retired partner with Deloitte, will provide oversight for DiaCarta's financial reporting process, audit process, system of internal controls, risk management, and compliance with laws and regulations.
He is also chairman of the audit committees and a member of the compensation committees of Dyadic International and UniQure.
Kaye has served on the boards of Keryx Biopharmaceuticals, Tongli Pharmaceuticals (USA), and Balboa Biosciences. He was a partner at Deloitte from 1978 until May 2006 when he retired.